Dr. Klingemann has served as the company’s Vice President of Research & Development since joining full time in 2012. He is also the discoverer of the NK-92 cell line and co-founder of the company. Dr. Klingemann received his M.D. from the University of Wurzburg Medical School, and his Ph.D. from the University of Marburg, Germany. He received specialty training in Stem Cell Transplantation under Nobel Laureate Dr. ED.
Thomas at the Fred Hutchinson Cancer Research Center in Seattle. Prior to joining NantKwest, Dr. Klingemann served as the Director of the Bone Marrow and Stem Cell Transplant Program and the Director for Hematological Malignancies at Tufts Medical Center in Boston. Dr. Klingemann also served as Director of the Section of Bone Marrow Transplant & Cell Therapy at Rush University Medical Center in Chicago where he established the first clinical GMP Cell Therapy facility in the Chicago area.
Over the past 25 years, Dr. Klingemann has conducted National Cancer Institute supported research on how to engineer the patient’s immune system to fight cancer, resulting in over 200 peer-reviewed publications. He is author and editor of several books on stem cell transplantation. Dr. Klingemann has been selected as Boston’s Top Doctor for the several years and was named by US News and World Report as one of the leading oncologists in the country. He maintains an academic appointment at Tufts University Medical School.